Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment; a Pilot-study

NCT02226757 Phase 2 UNKNOWN

This study is a pilot study in EGFR-mutated NSCLC patients who have progressed on standard-dose TKIs. Tumor biopsies will be evaluated for HER2-expression. In case of HER2 expression, patients can participate in the trial after obtaining informed consent. Patients will be treated with weekly paclitaxel-trastuzumab.

Details

Lead sponsor	Amsterdam UMC, location VUmc
Phase	Phase 2
Status	UNKNOWN
Enrolment	16
Start date	2014-08

Conditions

• NSCLC
• HER2-expression
• EGFR-mutation

Interventions

• Paclitaxel-trastzumab

Primary outcomes

• Objective response rate — 6 weeks

Countries

Netherlands